CD274 and lung carcinoma: Additionally, PD-L1 checkpoint inhibition and anti-PD-L1 antibodies are the most widely studied immunotherapy approaches in lung cancer, as well as, anti-PD-L1 antibodies are approved by the Food and Drug Administration for IHC-based diagnosis of lung cancer (Steven et al., 2016; Ancevski Hunter et al., 2018).